1 – 8 of 8
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response.
(
- Contribution to journal › Article
-
Mark
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance
(
- Contribution to journal › Article
- 2005
-
Mark
ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells.
(
- Contribution to journal › Article
-
Mark
Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
(
- Contribution to journal › Article
-
Mark
Microarray-based Analyses of Hypoxia-induced Transcriptional Changes in Breast Cancer Cell Lines
(
- Contribution to journal › Article
- 2004
-
Mark
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
(
- Contribution to journal › Article
- 2003
-
Mark
Regional cyclin D1 overexpression or hypoxia correlate inversely with heterogeneous oestrogen receptor-alpha expression in human breast cancer.
(
- Contribution to journal › Article
-
Mark
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ.
(
- Contribution to journal › Article